Stock AnalizAmphastar Pharmaceuticals, Inc. AMPH
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Amphastar Pharmaceuticals, Inc. (AMPH) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $746M and net income of $99M, a net margin of 13.3%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is value (5/5); the weakest is future growth (3/5).
Key numbers: a P/E of 13.4, a price to free cash flow of 9.0, 5-year revenue growth of 16% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 38% above the current price.
Score: 3.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- Revenue growth above 10% last year
- Profit margin improving
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $746M | $720M | $732M | $644M | $499M | $438M | $350M | $322M | $295M | $240M | $255M |
| Net income | $99M | $98M | $160M | $138M | $91M | $62M | $1M | $49M | -$6M | $4M | $10M |
| Free cash flow | $139M | $121M | $172M | $145M | $65M | $71M | $23M | $207000 | -$9M | $4M | $17M |
| EPS (diluted) | $2.19 | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | $-0.12 | $0.08 | $0.21 |
| Net margin | 13.3% | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | -1.9% | 1.5% | 3.9% |
| ROIC | — | 7.6% | 12.4% | 12.6% | 13.5% | 9.5% | 1.8% | -0.0% | -1.5% | -0.3% | 2.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $24.50, 17% below the current price; targets range from $20.00 to $30.00; the consensus rating is “Hold”; expected EPS is $3.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Amphastar Pharmaceuticals’s P/E ratio?
About 13.4, based on the last twelve months of diluted earnings per share (forward P/E about 10.8).
Is Amphastar Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 38% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Amphastar Pharmaceuticals pay a dividend?
Not currently.
Is Amphastar Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Amphastar Pharmaceuticals scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.